Numinus Bioscience is a global leader in supporting and expanding the safe, accessible, and evidence-based use of psychedelic-assisted therapies. Operating a state-of-the-art research facility in British Columbia, Canada, Numinus Bioscience holds a Controlled Drugs and Substances license issued by Health Canada to allow the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelic compounds and natural source materials, including psilocybe mushroom fruiting bodies and extracts, psilocybin, psilocin, ketamine, LSD, DMT, and mescaline.
Numinus has established itself at the forefront of psychedelic therapeutic development and as a supporting arm for psychedelic therapy clinical trials.
